Alzheimer's disease (AD) is the leading cause of dementia worldwide. Clinically, it is characterized by progressive cognitive decline, while neuropathologically, it is marked by amyloid-beta (Aβ) plaques, neurofibrillary tangles, synaptic dysfunction, gliosis, and neuroinflammation. Despite extensive research and significant investments, effective disease-modifying therapies remain elusive.
Traditional AD research has focused on genetics and canonical pathways, such as APP/PSEN mutations, APOE genotype, and amyloid/tau cascades. However, a pathogen hypothesis, which suggests that microbial agents may contribute to AD pathogenesis, has recently gained renewed interest. This review synthesizes current evidence linking infections to AD processes and explores the therapeutic implications.
Key Concepts & Proposed Mechanisms
Pathogen Entry into the Central Nervous System
The review outlines several pathways through which pathogens may invade the brain:
Through a compromised blood-brain barrier (BBB).
Along peripheral nerve tracts such as olfactory or trigeminal pathways.
Potentially via systemic inflammation that primes microglia and weakens neuroimmune defense.
Downstream Pathophysiological Effects
Once inside the central nervous system, pathogens may contribute to AD pathology through several overlapping mechanisms:
Neuroinflammation and Microglial Activation
Persistent infectious stimuli can chronically activate microglia and astrocytes, which release cytokines such as IL-1β and TNF-α, creating a pro-inflammatory environment that accelerates neuronal dysfunction.Interaction with Aβ and Tau Pathology
Pathogens may enhance the aggregation of Aβ and hyperphosphorylated tau or interfere with clearance mechanisms, further entrenching hallmark AD pathology.Disruption of Brain Homeostasis
Infection can perturb neuronal integrity, synaptic function, and the overall microenvironment of the aging brain, compounding other AD risk factors.
Microbial Candidates Implicated in AD
The review summarizes evidence, including clinical, epidemiological, and experimental data, for various infectious agents associated with AD-related changes:
Herpes simplex virus type 1 (HSV-1) — linked to increased amyloid deposition in some studies.
Periodontal and systemic bacteria such as Porphyromonas gingivalis — proposed to drive inflammation and modify amyloid pathways.
Chlamydia pneumoniae and fungal species — detected in some AD brain specimens and associated with local inflammation.
Other viruses like CMV and HIV, and systemic infections — suggested to contribute through immune modulation or vascular dysfunction.
Therapeutic Implications & Future Directions
Anti-Infective & Anti-Inflammatory Strategies
The review highlights that, if pathogens are causally linked to or accelerate AD, anti-pathogenic treatments (such as antivirals, antibiotics, and antifungals) or therapies targeting dysregulated neuroimmune responses could be potential adjunctive strategies. It calls for:
Rigorous clinical trials testing antimicrobial agents in early AD or at-risk populations.
Biomarker development for pathogen detection in the central nervous system.
Better mechanistic studies to distinguish cause from association.
Research Needs
Clarifying causal links between specific infections and AD progression.
Determining temporal relationships — whether pathogens trigger early pathology or exacerbate ongoing degenerative processes.
Integrating infection hypotheses with established mechanisms, such as amyloid/tau cascades and vascular contributions, in multifactorial models of AD.
Clinical Takeaways
The pathogen hypothesis does not negate traditional AD mechanisms but suggests that chronic or latent infections may interact with host immunity, aging, and genetic susceptibility to influence disease onset and progression.
Evidence is compelling but not yet definitive — diverse pathogens have been associated with AD pathology in experimental and some observational studies, but causal proof is lacking.
Future clinical research could explore targeted anti-infective interventions alongside anti-amyloid and anti-tau therapies.
Conclusion
This review provides an updated synthesis of the emerging evidence linking infectious agents to Alzheimer's disease mechanisms. It covers neuroimmunological pathways, microbial associations, and translational opportunities, positioning the pathogen hypothesis as a viable and testable dimension of AD research that may yield novel therapeutic insights.